MDM2 inhibition: an important step forward in cancer therapy
M Konopleva, G Martinelli, N Daver, C Papayannidis… - Leukemia, 2020 - nature.com
Targeting the interaction between tumor suppressor p53 and the E3 ligase MDM2
represents an attractive treatment approach for cancers with wild-type or functional TP53 …
represents an attractive treatment approach for cancers with wild-type or functional TP53 …
Targetable pathways in the treatment of retroperitoneal liposarcoma
Simple Summary This review discusses current and prospective treatment strategies for
retroperitoneal liposarcoma, a rare type of sarcoma with a high propensity for locoregional …
retroperitoneal liposarcoma, a rare type of sarcoma with a high propensity for locoregional …
A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097
S Jeay, S Gaulis, S Ferretti, H Bitter, M Ito, T Valat… - Elife, 2015 - elifesciences.org
Biomarkers for patient selection are essential for the successful and rapid development of
emerging targeted anti-cancer therapeutics. In this study, we report the discovery of a novel …
emerging targeted anti-cancer therapeutics. In this study, we report the discovery of a novel …